Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1384 • ACR Convergence 2024
Disease-modifying Antirheumatic Drugs and Risk of Incident Interstitial Lung Disease Among Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis
Qianru Zhang¹, Gregory McDermott², Sung Hae Chang³, Pierre-Antoine Juge⁴, Kathleen Vanni⁵, Grace Qian⁶, Katarina Bade⁵, Kevin Mueller⁵, Emily Kowalski⁵, Alene Saavedra⁵ and Jeffrey Sparks⁷, ¹Harard Medical School, Cambridge, ²Brigham and Women's Hospital, Brookline, MA, ³Soonchunhyang University College of Medicine, Bongmyeong-dong, Dongnam-gu, Cheonan-si, South Korea, ⁴Service de Rhumatologie, Hôpital Bichat - Claude-Bernard, AP-HP, Paris, Île-de-France, France, PARIS, Germany, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Brigham and Women’s Hospital, Boston, MA, ⁷Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA
Background/Purpose: Interstitial lung disease (ILD) is a serious extra-articular manifestation of RA, affecting 7-12% of patients and associated with three-fold increased mortality compared to RA…
Abstract Number: 1400 • ACR Convergence 2024
Disease Modifying Anti-rheumatic Drug Use and Association with Survival in Patients with Rheumatoid Arthritis and Newly Diagnosed Lung Cancer
Varun Nandakumar¹, Aaron Baraff², Alexander Peterson², Nicholas Smith³, Jennifer Barton⁴, Ann O'Hare², Christopher Li⁵, Noel Weiss³ and Namrata Singh⁶, ¹AIIMS, New Delhi, Delhi, India, ²VA PUGET SOUND SEATTLE, Seattle, WA, ³University of Washington, Seattle, WA, ⁴VA Portland Health Care System/OHSU, Portland, OR, ⁵University of Washington, Seattle, ⁶University of Washington, Bellevue, WA
Background/Purpose: Despite the significant therapeutic benefits of various disease modifying anti-rheumatic drugs (DMARDs) in RA, concerns remain regarding their safety, particularly their potential impact on…
Abstract Number: 1679 • ACR Convergence 2024
Differential Pharmacodynamic Changes of Circulated Immune Subsets After Treatment with Abatacept or Adalimumab in Patients with ACPA+ Early RA in the AMPLIFIED Study
Nathanial Eddy¹, Jane Buckner², Paul Emery³, Michael Weinblatt⁴, Vivian Bykerk⁵, Andrew Cope⁶, Gerd Burmester⁷, Yoshiya Tanaka⁸, Gustavo Citera⁹, Peter Nash¹⁰, Quentin Dornic¹¹, Peter Schafer¹², Sheila Kelly¹³, Michael Maldonado¹¹ and Jinqi Liu¹¹, ¹Bristol Myers Squibb, Princeton, ²Benaroya Research Institute, Seattle, WA, ³University of Leeds, Leeds, United Kingdom, ⁴Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, ⁵Hospital For Special Surgery, New York, NY, ⁶King's College London, London, United Kingdom, ⁷Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁸Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ⁹Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ¹⁰Griffith University, Brisbane, Australia, ¹¹Bristol Myers Squibb, Princeton, NJ, ¹²Bristol Myers Squibb, BELLE MEAD, NJ, ¹³Bristol Myers Squibb, Doylestown, PA
Background/Purpose: Despite considerable advances in pharmacologic approaches to RA management, a better understanding of the underlying immunopathology is still needed.1,2 A dysregulated immune system is…
Abstract Number: 1836 • ACR Convergence 2024
Transcriptional Changes in the Formation of Tissue Resident Memory T Cells in the Joint
Yang Yang¹, Yusuke Miyashita¹, Vitor Aguiar¹, Maria Gutierrez-Arcelus¹, Kellen Winden², Peter Nigrovic³ and Margaret Chang¹, ¹Boston Children's Hospital, Boston, MA, ²Boston Children's Hospital, Boston, MA, ³Boston Children's Hospital, Brookline, MA
Background/Purpose: Rheumatoid arthritis is a chronic autoimmune disease characterized by joint-specific memory, the phenomenon in which arthritis repeatedly flares in the same joints. We previously…
Abstract Number: 1899 • ACR Convergence 2024
Recurrent Heart Failure Hospitalization in Rheumatoid Arthritis: A National Veterans Affairs Matched Cohort Study
Tate Johnson¹, Yangyuna Yang¹, Punyasha Roul², Joshua Baker³, Gary Kunkel⁴, Sauer brian⁵, grant Cannon⁶, Ted Mikuls¹ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²UNMC, Omaha, NE, ³University of Pennsylvania, Philadelphia, PA, ⁴University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁵Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁶University of Utah and Salt Lake City VA, Salt Lake City, UT
Background/Purpose: People with rheumatoid arthritis (RA) are at an increased risk of heart failure (HF), which is among the most burdensome chronic conditions and a…
Abstract Number: 1989 • ACR Convergence 2024
Higher Early Cumulative Glucocorticoid Exposure Is Associated with Worse Progression-Free Survival in Patients with Immune Checkpoint Inhibitor Inflammatory Arthritis
Minerva Nong¹, Deanna Jannat-Khah², Karmela Kim Chan², Nilasha Ghosh³ and Anne Bass⁴, ¹Hospital for Special Surgery, Tampa, FL, ²Hospital For Special Surgery, New York, NY, ³Hospital for Special Surgery, New York, NY, ⁴Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Although immune checkpoint inhibitors (ICI) have transformed cancer treatment, they unleash a range of immune-related adverse events (irAE), including inflammatory arthritis (ICI-IA). Glucocorticoids are…
Abstract Number: 2214 • ACR Convergence 2024
Confirming a Value for Rheumatoid Arthritis Flares Based on Changes in CDAI, SDAI and RAPID3
Irtza Badar¹ and Martin Bergman², ¹Mercy Catholic Medical Center, Philadelphia, PA, ²self, Beach Haven, NJ
Background/Purpose: To determine and revalidate the definitions of disease flares in patients with rheumatoid arthritis (RA) flares based on the changes in Clinical and Simplified…
Abstract Number: 2231 • ACR Convergence 2024
Treatment Response over the First 6 Months in Newly Diagosed RA Patients by Pain, Anxiety, Depression & Fatigue (PADF) Symptom Clusters: Results from the Canadian Early Arthritis Cohort
Susan Bartlett¹, Orit Schieir², Marie-France Valois¹, Louis Bessette³, Janet Pope⁴, Gilles Boire⁵, Carol Hitchon⁶, Ed Keystone⁷, Carter Thorne⁸, Diane Tin⁸, Glen Hazlewood⁹, Hugues Allard-Chamard¹⁰, Bindee Kuriya¹¹, Vivian Bykerk¹² and Clifton Bingham¹³, and Investigators with the Canadian Early Arthritis Cohort (CATCH), ¹Centre for Outcomes Research & Eval, Montreal, QC, Canada, ²McGill University, Montreal, QC, Canada, ³University of Laval, Quebec City, QC, Canada, ⁴University of Western Ontario, London, ON, Canada, ⁵Retired, Sherbrooke, QC, Canada, ⁶University of Manitoba, Winnipeg, MB, Canada, ⁷Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁸Newmarket Rheumatology Consultants, Newmarket, ON, Canada, ⁹University of Calgary, Calgary, AB, Canada, ¹⁰University of Sherbrooke, Sherbrooke, QC, Canada, ¹¹University of Toronto - Toronto, Toronto, ON, Canada, ¹²Hospital for Special Surgery, New York, NY, ¹³Johns Hopkins University, Baltimore, MD
Background/Purpose: Growing evidence suggests that across chronic diseases, patients with co-occurring symptoms of pain, anxiety, and depression (PAD), known as “symptom clusters”, experience variable disease…
Abstract Number: 2247 • ACR Convergence 2024
Pro-inflammatory Monocytes and CD11c Expression in ACPA Positive Individuals with Arthralgia and Their Associations with Subclinical Synovitis Preceding the Onset of Arthritis
Klára Prajzlerová¹, Olga Kryštufková², Petra Hánová¹, Nora Růžičková², Hana Hulejová¹, Jiří Vencovský², Ladislav Šenolt² and Mária Filková², ¹Institute of Rheumatology, Prague, Czech Republic, ²Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
Background/Purpose: Autoantibodies, e.g., against citrullinated proteins (ACPA), increase the risk of clinical arthritis and can be detected years before rheumatoid arthritis (RA) onset. EULAR's definition…
Abstract Number: 2268 • ACR Convergence 2024
The Discontinuation and Effectiveness of Sequential Advanced Therapy in Rheumatoid Arthritis, a Real-World Data
Mohammad Movahedi¹, Angela Cesta², Xiuying Li², Bindee Kuriya³, Sibel Aydin⁴, Claire Bombardier⁵ and Pooneh Seyed-Akhavan⁶, and OBRI investigators, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²UHN, Toronto, ON, Canada, ³University of Toronto - Toronto, Toronto, ON, Canada, ⁴Ottawa Hospital Research Institute, Ottawa, ON, Canada, ⁵University of Toronto, Toronto, ON, Canada, ⁶Sinai Health System, Toronto, ON, Canada
Background/Purpose: Patients with rheumatoid arthritis (RA) who fail conventional synthetic treatment with disease modifying anti-rheumatic drugs (csDMARDs) are eligible for biological DMARDs (bDMARDs) or targeted…
Abstract Number: 2285 • ACR Convergence 2024
Safety and Tolerability of a Combination of Curcumin, Omega-3 and Vitamin-D: Results from the PASCOD Study, an RA Prevention Protocol
Halle Cochrane, Caitlin Mcfadyen, Kale Mayor, Rhonda Silva, Kristin James, Xiaobo Meng, Dylan Mackay, Hani El-Gabalawy and Liam O'Neil, University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Rheumatoid Arthritis (RA) is a progressive inflammatory autoimmune disease affecting 1% of the global population for which there is currently no cure. Recent research…
Abstract Number: 2593 • ACR Convergence 2024
A Long-term Synovial Tissue 3D Model Incorporating Fibroblasts, Macrophages, Endothelial Cells, and Other Immune Cells Such as Innate Lymphoid Cells Enables Animal Model-Independent Rheumatoid Arthritis Research
Miriam Bollmann¹, Oskar Landberg², Negar Ayoubzadeh², Charlotte A. Jonsson², Inger Gjertsson² and Mattias Svensson², ¹University of Gothenburg, Göteborg, Sweden, ²University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory joint disease with multiple tissues contributing to its pathology, including the synovial membrane. The RA synovial membrane…
Abstract Number: PP01 • ACR Convergence 2024
An OCEAN of Change: The Impact of an RA Diagnosis on My Big Five Personality Traits
Laura Sambursky¹ and Lauren Sambursky², ¹Patient, Sarasota, FL, ²Northeastern University, Boston, MA
Background/Purpose: Until age 32, I was a healthy, confident, extraverted, and creative person. I moved hundreds of miles away for college and then earned a…
Abstract Number: 0033 • ACR Convergence 2024
Refined Autoantibody Profiles in RA Reveal That Primarily ACPAs Binding Non-glycine Citrulline Motifs Are Associated with Shared Epitope Alleles
Linda Mathsson-Alm¹, Helga Westerlind², Isabel Gehring³, Monika Hansson², Nasim Ghasemzadeh¹, Jessica Rojas-Restrepo³, Saedis Saevarsdottir⁴, Joseph Sexton⁵, Siri Lillegraven⁶, Espen Haavardsholm⁶, Merete Hetland⁷, Hilde Hammer⁸, Tore K. Kvien⁹, Bente Glintborg¹⁰, Leonid Padyukov², Johan Askling² and Caroline Grönwall², and the Danish Rheumatologic Biobank Study Group (the Biomarker Protocol), Swedish Rheumatology Quality Register Biobank Study Group (SRQb), ¹Thermo Fisher Scientific, Uppsala, Sweden, ²Karolinska Institutet, Stockholm, Sweden, ³Thermo Fisher Scientific, Freiburg, Germany, ⁴University of Iceland, Reykjavik, Iceland, ⁵Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, ⁶Diakonhjemmet Hospital, Oslo, Norway, ⁷Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark, ⁸Diakonhjemmet Hospital, Oslo, Oslo, Norway, ⁹Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, ¹⁰DANBIO, Rigshospitalet Glostrup and University of Copenhagen, Virum, Denmark
Background/Purpose: Carriage of HLA-DRB1 shared epitope (SE) alleles and a history of smoking, have been identified as the most prominent risk factors for development of…
Abstract Number: 0049 • ACR Convergence 2024
Inflammatory Priming by Anti-MAA Antibodies in Rheumatoid Arthritis
Marcelo Afonso¹, Jitong Sun¹, Koji Sakuraba¹, Alexandra Circiumaru², Denis Lagutkin¹, Masa Filipovic¹, Anca Catrina¹, Caroline Grönwall¹, Aase Hensvold¹ and Bence Réthi¹, ¹Karolinska Institutet, Stockholm, Sweden, ²Division for Rheumatology, Karolinska Institutet; Center for Rheumatology, Academic Specialist Center, Stockholm region, Stockholm, Sweden
Background/Purpose: We have previously shown that autoantibodies targeting malondialdehyde-acetaldehyde protein adducts (anti-MAA) in rheumatoid arthritis (RA) patients boosted osteoclast differentiation and induced bone erosion in mice…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].